Reference to Patient-Reported Outcomes and Preferences

The Ministry of Food and Drug Safety will now reflect patients' real-life experiences—such as symptoms encountered during actual treatment—in the expedited review process for therapies targeting rare and severe diseases.

Food and Drug Safety Administration building in Cheongju, Chungbuk. The Asia Business Daily DB

Food and Drug Safety Administration building in Cheongju, Chungbuk. The Asia Business Daily DB

View original image

On August 28, the National Institute of Food and Drug Safety Evaluation, under the Ministry of Food and Drug Safety, announced that it had revised the "Considerations for Priority Review Designation Application of Medical Products" in order to systematically incorporate patients' experiences and perspectives into the review of the Global Innovation Product Fast-Track (GIFT) program.


The GIFT program is a system for rapidly reviewing highly innovative medical products that treat life-threatening or rare diseases.


Under this revision, pharmaceutical and biotechnology companies will be able to submit patient experience data (PED) at the application stage for GIFT designation. This aims to supplement clinical trial results by providing insight into symptoms and functional status, quality of life, and specific challenges patients face during treatment—all of which are difficult to fully capture with clinical data alone.


To support this, the Ministry of Food and Drug Safety has added a patient experience data checklist to the GIFT application form. Companies can indicate the type of documents submitted and whether or not PED are being included, enabling them to attach relevant materials. The guideline has also been updated with a more detailed explanation of the "serious diseases" that are eligible for GIFT designation.


Patient experience data that can be submitted include: ▲ clinical evaluation data such as patient-reported outcomes (PRO), where patients directly assess their symptoms or quality of life; ▲ research analyzing patient preferences regarding treatment efficacy, adverse events, administration method, or duration of therapy; ▲ qualitative research such as interviews with patients or caregivers; and ▲ materials related to patient engagement activities, such as patient video diaries, audio recordings, or written opinions.


Previously, the Ministry of Food and Drug Safety reviewed GIFT designation applications focusing primarily on factors such as disease severity, the availability of alternative therapies, and improvements in safety or efficacy compared to existing drugs. Moving forward, when companies submit patient experience data, these materials will be used as supplementary references to assess both the disease burden and the risk-benefit profile of the therapy in question.


The Ministry stated, “We plan to systematically incorporate the experiences and perspectives of patients—the primary users of medicines—into the GIFT designation review process, and to support the swift approval of therapies that rare and severely ill patients and their families can truly experience in practice.”



This content was produced with the assistance of AI translation services.

© The Asia Business Daily. All rights reserved. Unauthorized AI training and use prohibited.

Today’s Briefing